Grünenthal completes acquisition of Empresas Andrómaco

Aachen / Santiago de Chile (ots) -

- 81.59% of share capital of Laboratorios Andrómaco S.A. acquired
in public tender offer
- Grünenthal realizes major step in its growth strategy by almost
doubling revenues in the Latin American region
- Both companies together represent approx. 450 Mio. USD in
revenues in the region

The Grünenthal Group today announced the acceptance of the public
tender offer with respect to the acquisition of all issued and
outstanding shares of Laboratorios Andrómaco S.A. Inversiones Gruchi
Limitada, a subsidiary of Grünenthal GmbH, Germany, has acquired
81.59% of all issued and outstanding shares of Laboratorios Andrómaco
S.A. through a public tender offer. The offer period ended on
December 24, 2013. Shareholders of Laboratorios Andrómaco S.A. who
tendered their shares receive CLP 332.48 per share in cash.

Professor Dr. Eric-Paul Pâques, CEO of Grünenthal Group said: "We
are very pleased with the result of the tender offer. The
overwhelming majority of Andrómaco shareholders have tendered their
shares. In our long-term strategy, we had confirmed Latin America as
the key market for the company's future growth based on the overall
market expectations as well as our long-established presence and
experience in the region. That is why the acquisition is also to be
seen as a milestone in the implementation of our global growth
strategy. With Empresas Andrómaco, we acquire the best regional
company to complement our own business and our therapeutic areas in
the Andean countries and Central America. This important step will
enable us to take the operation of both companies in Latin America to
the next level. I welcome all employees of Empresas Andrómaco to the
Grünenthal Group family. Grünenthal keeps further seeking after
additional businesses in Mexico and Brazil."

Oscar Ferenczi, Grünenthal's Executive Vice President Latin
America, added: "After the successful public tender offer, we can now
start to bring the two businesses together across the region. We will
work together with our new colleagues on a blueprint for this
important next phase and I look forward to working with the
management team across the region to start the implementation. What
we learned so far about Empresas Andrómaco has reinforced our
original assessment that there is not only a clear strategic fit in
terms of regional footprint and therapeutic areas but also a cultural
fit among the two companies. We will build on this as we bring this
combination to life in the coming months and years."

"I am very happy with the result of this process. I see it as a
great opportunity for Andrómaco and for all its employees.
Incorporating a strategic industry partner is a recognition of what
we have done", said Sergio Weinstein, former majority shareholder and
Vice President of Andrómaco. "This success is the result of a long
term project that is now entering a new stage", added Weinstein.

With the addition of the Empresas Andrómaco business, Grünenthal
will have affiliates in Bolivia, Brazil, Chile, Colombia, Costa Rica,
Ecuador, Guatemala, Mexico, Panama, Peru and Venezuela and partner
activities in Argentina, Dominican Republic, Honduras, Nicaragua,
Paraguay, El Salvador and further Central American countries and the
Caribbean. In 2012, pro-forma revenues in Latin America of the
combined business of Empresas Andrómaco and Grünenthal amounted to
approx. USD 450 mn and together the two Groups employed more than
2,300 people in the region.

About Grünenthal

The Grünenthal Group is an independent, family-owned,
international research-based pharmaceutical company headquartered in
Aachen, Germany. Building on its unique position in pain treatment,
its objective is to become the most patient-centric company and thus
to be a leader in therapy innovation. Grünenthal is one of the last
five remaining research-oriented pharmaceutical companies with
headquarters in Germany which sustainably invests in research and
development. Research and development costs amounted to about 26
percent of revenues in 2012. Grünenthal's research and development
strategy concentrates on selected fields of therapy and
state-of-the-art technologies. We are intensely focused on
discovering new ways to treat pain better and more effectively, with
fewer side-effects than current therapies. Altogether, the Grünenthal
Group has affiliates in 26 countries worldwide. Grünenthal products
are sold in more than 155 countries. Today, approx. 4,400 employees
are working for the Grünenthal Group worldwide. In 2012, Grünenthal
achieved revenues of E973 mn. More information: www.grunenthal.com.

Contact:
Frank Schönrock, Vice President Public Engagement
Tel.: +49 241 569-1568, Fax: +49 241 569-3539,
frank.schoenrock@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Deutschland,
www.grunenthal.com